Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANPC

AnPac Bio-Medical Science Co., Ltd.

Healthcare · Biotechnology

$4.30

Down-$0.14 (-3.15%)

Updated Nov 5, 2026, 4:21 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
26.97M
P/E ratio
-0.54
Dividend yield
0.00%
52-week range
— – —
Volume
35.7K
Avg. volume
21.49K

Price performance · ANPC

ANPC price history

1M range · 0 trading sessions · Daily adjusted prices

ANPC does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ANPC news

The latest Smart Investors Daily articles mentioning ANPC.

Stock researchCompany · Overview

ANPC research

Overview

Company profile and research snapshot.

Company profile

AnPac Bio-Medical Science Co., Ltd., a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup package services. The company was incorporated in 2010 and is headquartered in Lishui, the People's Republic of China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.16
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Apr 1, 2023

AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering

New York, NY, March 31, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase $3.0 million of its American Depositary Shares (“ADSs”), pre-funded warrants to purchase ADSs and warrants to purchase ADSs in a registered direct offering.  The Company plans to use the net proceeds from the offering for the advancement of our research and development activities, working capital and general corporate purposes.

Benzinga · Feb 1, 2023

Electronic Arts, Western Digital And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. Snap Inc. (NYSE: SNAP) shares dipped 14.6% to $9.87 in pre-market trading after the company posted a net loss for the fourth quarter and said revenue could drop by as much as 10% for the current quarter. AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) shares fell 14.4% to $7.27 in pre-market trading. AnPac Bio-Medical Science announced signing of $5.2 million ...

GlobeNewswire Inc. · Jan 25, 2023

AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements

New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business food e-commerce company, announced that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors. The investors agreed to purchase 29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or “ADSs”) of the Company at a price of US$0.175 per ordinary share or US$3.50 per ADS (1:20 ADS-to-share ratio), for a total purchase price of US$5.2 million. The closing is expected to take place within 30 days after signing. Concurrently, for each Class A ordinary share purchased, the investors will receive two warrants with each warrant to purchase one Class A ordinary share at an exercise price of US$0.21 per ordinary share (2,971,428 ADS an at exercise price of US$4.20 per ADS). The warrants will be exercisable within 2 years from the date of issuance.

GlobeNewswire Inc. · Jan 20, 2023

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing

New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection announced that, on January 13, 2023, it received a Staff determination letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company of the Staff’s determination to delist the Company’s securities from The Nasdaq Capital Market due to the Company’s failure to comply with the minimum $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Equity Rule”), unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing. The hearing request will automatically stay any delisting or suspension action relating to the Company’s American Depositary Shares through the hearing and the expiration of any additional extension period granted by the Panel following the hearing.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By